{"filing":{"accession_number":"0001193125-26-261661","cik":"0001817229","ticker":"VOR","company_name":"Vor Biopharma Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"vor-20260608.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526261661/vor-20260608.htm"},"events":[{"id":6187,"run_id":5433,"accession_number":"0001193125-26-261661","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Vor Biopharma announced that its partner RemeGen received conditional approval from China's NMPA for telitacicept in IgA nephropathy and full approval in Sjögren's disease. This represents a material regulatory milestone for a product in the company's pipeline, affecting investor assessment of the company's commercial prospects and partnership value. However, the event does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, or executive change), warranting classification as other_material.","company_name":"Vor Biopharma Inc.","ticker":"VOR","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5149,"accession_number":"0001193125-26-261661","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Vor Biopharma announced that its partner RemeGen received conditional approval from China's NMPA for telitacicept in IgA nephropathy and full approval in Sjögren's disease. This represents a material regulatory milestone for a product in the company's pipeline, affecting investor assessment of the company's commercial prospects and partnership value. However, the event does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, or executive change), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:04:06.184278+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5149,"accession_number":"0001193125-26-261661","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Vor Biopharma announced that its partner RemeGen received conditional approval from China's NMPA for telitacicept in IgA nephropathy and full approval in Sjögren's disease. This represents a material regulatory milestone for a product in the company's pipeline, affecting investor assessment of the company's commercial prospects and partnership value. However, the event does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, or executive change), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:04:06.184278+00:00","company_name":"Vor Biopharma Inc.","ticker":"VOR","filing_date":"2026-06-08"}]}